Mild or moderate vitamin D deficiency Nutritional, Metabolic, Endocrine Vitamin D deficiency
Conditions
Interventions
Supplementation with either calcium and vitamin D or calcium alone. The subjects will be treated with two tablets per day for twelve months. The allocation of subjects to treatment, study product (vit
Sponsors
Recip AB (Sweden)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Men and women 55 to 85 years of age 2. Mild or moderate vitamin D insufficiency (serum 25-hydroxy-vitamin D 10-70 nmol/L)
Exclusion criteria
Exclusion criteria: 1. Subjects with severe vitamin D deficiency (serum 25-hydroxy-vitamin D below 10 nmol/L) 2. Suspected osteomalacia 3. Serious diseases or drug treatments that may interfere with study results
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum levels of 25-hydroxyvitamin D, measured at baseline, 3, 6, 9 and 12 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Serum levels of parathyroid hormone and biochemical bone markers, measured at baseline, 6 and 12 months 2. Safety, measured at baseline, 3, 6, 9 and 12 months | — |
Countries
Sweden
Outcome results
None listed